Manila Times Business
RadioMedix Announces Receiving FDA Approval of its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate Cancer
Approval follows FDA inspection of RadioMedix’s manufacturing site with no Form 483 observations, underscoring the Company’s radiopharmaceutical manufacturing and quality capabilities HOUSTON, June 10, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s GALLIUM GA 68 GOZETOTIDE
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
The ChariTree Foundation Calls for More Outdoor Learning Opportunities for Children in the Age of AI
Just now
Budweiser China Co-Hosts Global Night-Time Economy Dialogue in Shanghai, Highlighting Multinational Companies’ Role in Urban Consumption Growth
Just now
Completion of the Sale of the Share of Saare Kala Tootmine OÜ
Just now
Shufti Ranked as a Leader in G2’s Summer 2026 Identity Verification Grid® Report
Just now